Leeds AI spinout adsilico raises £10M to test medical devices on virtual patients
University of Leeds spinout adsilico has raised £10 million in a SeriesA funding round to expand its AI-powered simulation technology for assessingmedical device performance across diverse virtual pat...
Leeds-based AI spinout adsilico has secured £10 million in Series A funding to enhance its AI-powered simulation technology that evaluates medical device performance across diverse virtual patient populations. Led by investors PXN Ventures, Northern Gritstone, and Parkwalk, the funding round supports the company's mission to assist medical device manufacturers in assessing implant performance before clinical trials.
Founded in 2024 by Sheena Macpherson, Dr Nishant Ravikumar, and Dr Zeike Taylor, adsilico's technology aids in creating virtual hearts and blood vessels from anonymised clinical scans using generative AI. This platform, known as Virtual Chimera, allows manufacturers to test device performance across various patient demographics, including age, sex, ethnicity, body size, and medical conditions.
By providing additional data to existing testing methods, adsilico aims to identify potential issues earlier, support targeted studies, and potentially reduce reliance on animal testing. The new funding will enable adsilico to further develop its virtual heart models, expand into neurovascular devices, and grow its workforce as it ventures into additional therapeutic areas.
CEO and co-founder Sheena Macpherson emphasizes the importance of ensuring that patients with diverse anatomical backgrounds are represented in the design and testing of medical devices to prevent complications and enhance patient outcomes.
Written by urgent.news from Tech.eu's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
